{
  "abstract": "Background: With improved survival among people living with HIV (PLWH), non-AIDS-defining cancers have become increasingly prominent. Women living with HIV (WLWH) remain underrepresented in ovarian cancer trials, leaving limited evidence on the tolerability of standard therapies, including chemotherapy, anti-VEGF agents, and PARP inhibitors. These patients also face unique care barriers beyond biological uncertainties.\n\nMethods: This retrospective review included five WLWH diagnosed with ovarian cancer (June 2022–March 2024). Three received anticancer treatment; one refused chemotherapy and was lost to follow-up; one had biopsy only. We collected data on demographics, HIV history, tumor characteristics, treatment exposure, adverse events (CTCAE v5.0), CD4 ⁺ /CD8 ⁺ counts, and HIV RNA, focusing safety and immune analyses on the three treated patients.\n\nResults: Median age was 51 years; four had stage III–IV disease. No treatment-related deaths, persistent HIV rebound, or AIDS-defining events occurred. During first-line paclitaxel/carboplatin, one patient developed grade 3 neutropenia managed with G-CSF, but later developed significant thrombocytopenia on niraparib requiring dose reduction and hospitalization. Among two patients receiving bevacizumab, CD4 ⁺ patterns diverged: one showed a transient decline (387 to 259 cells/μL) with concurrent nedaplatin; another maintained stable counts (150 to 200 cells/μL). One patient had transient, self-limited HIV RNA elevation concurrent with disease progression, which resolved spontaneously.\n\nConclusion: This series provides real-world observations that platinum-based and targeted therapies may be delivered to selected WLWH with close monitoring. The heterogeneous CD4 ⁺ responses highlight the need for individualized immune surveillance rather than attributing changes to any single agent. Integrated oncologic-HIV care and attention to socioeconomic barriers remain critical for this underrepresented population.",
  "abstract_shown": true,
  "affiliations": [
    "Shenzhen Third People’s Hospital , , ,",
    "South China Hospital, Medical School, Shenzhen University , , ,",
    "Shenzhen University General Hospital , , ,"
  ],
  "article_type": "research article",
  "arxiv": null,
  "author_total": 9,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Yang Zhang"
    },
    {
      "affs": [
        0
      ],
      "name": "Fuxiang Wang"
    },
    {
      "affs": [
        1
      ],
      "name": "Mingchuan Guo"
    },
    {
      "affs": [
        0
      ],
      "name": "Jianyu Wan"
    },
    {
      "affs": [
        0
      ],
      "name": "Huiyan Liao"
    },
    {
      "affs": [
        0
      ],
      "name": "Ting Mao"
    },
    {
      "affs": [
        0
      ],
      "name": "Lu Cui"
    },
    {
      "affs": [
        2
      ],
      "name": "Wenming Cao"
    },
    {
      "affs": [
        0
      ],
      "name": "Yutao Gao"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/1fzkt624rhwyt.bib",
  "cited_by": 1,
  "doi": "10.3389/fonc.2026.1942370",
  "fulltext_url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13661414/?tool=EBI",
  "id": "1fzkt624rhwyt",
  "issns": [
    "2234-943X"
  ],
  "landing_url": "https://europepmc.org/article/PMC/PMC13661414",
  "language": "eng",
  "licence": "CC-BY",
  "licence_label": "CC BY",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "openalex",
      "2743|Ovarian cancer diagnosis and treatment"
    ]
  ],
  "openalex": "W7214909646",
  "pdf_url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13661414/pdf/?tool=EBI",
  "pmcid": "PMC13661414",
  "pmid": null,
  "published": "2026-09-30",
  "publisher": "Frontiers Media SA",
  "ris": "https://research.draconitic.com/paper/1fzkt624rhwyt.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T12:17:20Z",
      "native_id": "PMC:PMC13661414",
      "source": "europepmc",
      "url": "https://europepmc.org/article/PMC/PMC13661414"
    },
    {
      "first_seen": "2026-10-30T12:20:13Z",
      "native_id": "10.3389/fonc.2026.1942370",
      "source": "crossref",
      "url": "https://www.frontiersin.org/articles/10.3389/fonc.2026.1942370/full"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2743|Ovarian cancer diagnosis and treatment",
      "subfield": "reproductive-child"
    }
  ],
  "title": "Real-world management of ovarian cancer in women living with HIV: treatment exposure, immune monitoring, and care barriers in a five-case series",
  "title_text": "Real-world management of ovarian cancer in women living with HIV: treatment exposure, immune monitoring, and care barriers in a five-case series",
  "type": "peer-reviewed",
  "updated_at": "2026-10-30T12:20:13Z",
  "url": "https://research.draconitic.com/paper/1fzkt624rhwyt",
  "venue": "Frontiers in oncology",
  "versions": []
}